Stock Report

Download full stock data and analysis for free Last Updated: 27-Oct-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Beta Drugs Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: BETA

₹1,934.20

up-down-arrow ₹-43.70 (-2.21%)

As on 27-Oct-2026IST

Market cap

info icon

₹2,151 Cr

Revenue (TTM)

info icon

₹444 Cr

P/E Ratio

info icon

41.4

P/B Ratio

info icon

4.9

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 9.51 32.99 15.20 19.22 27.08
EBIT 11.51 50.40 19.55 11.07 26.78
Net Profit 17.40 51.83 14.62 10.53 28.75
EPS 17.03 37.83 16.28 10.53 28.75
Book Value -- -- 23.67 25.65 28.86
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-26Mar-25
EBIT-Margin info 11.2817.4816.6915.2117.14
Net Margin info 7.9612.2311.7810.4811.50
Return on equity info 14.5225.6315.2118.7823.95
Return on Capital info 17.3329.49--19.1625.23
Return on Assets info 8.2114.1316.258.7711.99
Debt to Equity (x) info ----0.060.600.70

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
--
19.16
25.23
32.74
33.94
Peer Median
--
14.90
14.72
18.85
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

15.21

Higher than Peers by 4.36

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
15.21
18.78
23.95
26.03
28.55
Peer Median
10.86
12.42
11.67
14.92
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

16.25

Higher than Peers by 9.50

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
16.25
8.77
11.99
15.63
16.74
Peer Median
6.76
7.49
7.86
9.06
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

16.69

Higher than Peers by 4.00

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
16.69
15.21
17.14
16.98
18.81
Peer Median
12.69
15.05
15.03
14.71
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

11.78

Higher than Peers by 2.92

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
11.78
10.48
11.50
12.27
13.48
Peer Median
8.86
8.42
9.33
8.49
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
--
15.24
15.16
15.63
18.11
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

15.20

Higher than Peers by 7.06

Year on year growth in net sales

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
15.20
6.20
22.54
30.21
23.54
Peer Median
8.14
14.66
10.27
11.85
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

19.55

Higher than Peers by 2.21

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
19.55
-5.74
23.65
17.55
20.52
Peer Median
17.34
20.57
24.15
28.00
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

14.62

Lower than Peers by 2.62

Year on year growth in profit after tax

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
14.62
-2.21
16.42
18.62
23.73
Peer Median
17.25
27.81
30.29
36.51
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

16.28

Higher than Peers by 5.68

Year on year growth in earnings per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
16.28
-2.20
16.41
18.62
23.73
Peer Median
10.60
10.32
24.50
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
--
24.19
25.45
27.86
33.07
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

0.06

Higher than Peers by 0.02

Total debt / Net worth

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
0.06
0.60
0.70
0.09
0.17
Peer Median
0.04
0.25
0.23
0.20
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
--
0.03
0.03
0.03
0.07
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

2.63

Higher than Peers by 0.90

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
2.63
2.96
2.92
1.99
1.93
Peer Median
1.73
1.82
1.79
1.96
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

2.06

Higher than Peers by 0.89

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
2.06
2.32
2.39
1.55
1.49
Peer Median
1.17
1.26
1.47
1.44
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

6.57

Lower than Peers by 1.24

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
6.57
4.55
9.15
18.29
18.00
Peer Median
7.82
7.80
9.42
8.58
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

37.69

Higher than Peers by 11.73

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
37.69
30.96
28.31
26.80
27.62
Peer Median
25.96
25.37
25.82
26.12
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

1.35

Higher than Peers by 0.69

Sales / Average Total Assets

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
1.35
0.81
1.02
1.27
1.24
Peer Median
0.67
0.75
0.75
0.77
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
--
105.14
91.57
87.61
86.71
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
--
63.66
55.19
49.64
42.67
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
--
161.92
139.01
121.55
124.66
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
--
6.88
7.75
15.70
4.72
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

41.43

Lower than Peers by 1.01

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
41.43
28.94
45.35
31.00
19.62
Peer Median
42.44
42.40
39.70
33.48
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

4.91

Higher than Peers by 0.52

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
4.91
4.93
9.76
7.55
4.90
Peer Median
4.39
4.58
3.72
4.21
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
--
--
--
--
--
Peer Median
0.11
0.11
0.16
0.21
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

20.78

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
20.78
14.14
23.62
19.10
11.21
Peer Median
--
30.25
30.23
29.90
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

2,151

Lower than Peers by 5,311

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Beta Drugs
2,151
1,206
1,924
1,186
603
Peer Median
7,462
5,056
4,851
2,099
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...

Mutual Fund Insight turns 24! 🎉 Get 2 FREE anniversary guides: The Right SIP + The Big Funds